Richardson Des R
The Iron Metabolism and Chelation Group, The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney, New South Wales, 2050 Australia.
Adv Exp Med Biol. 2002;509:231-49. doi: 10.1007/978-1-4615-0593-8_12.
The success of DFO at markedly inhibiting the growth of aggressive tumors such as neuroblastoma and leukemia justifies interest in the development of chelators as anti-neoplastic agents. This is emphasized by the fact that DFO has suboptimal properties, namely poor membrane permeability and a very short serum half-life. More recently, the thiosemicarbazone chelator, Triapine, has entered a phase I clinical trial again confirming the potential of these compounds. Further studies examining the effects of chelators on neoplastic cells will not only be valuable in terms of identifing novel anti-cancer agents, but will also provide new information on the role of Fe in cell cycle control.
去铁胺（DFO）能显著抑制成神经细胞瘤和白血病等侵袭性肿瘤的生长，这一成果使得人们对开发螯合剂作为抗肿瘤药物产生了兴趣。去铁胺具有一些不理想的特性，即膜通透性差和血清半衰期极短，这一事实凸显了上述兴趣。最近，硫代氨基脲螯合剂曲洛铁已进入I期临床试验，再次证实了这些化合物的潜力。进一步研究螯合剂对肿瘤细胞的作用，不仅在鉴定新型抗癌药物方面具有重要价值，还将为铁在细胞周期调控中的作用提供新的信息。
